IDRSF News and Press, Idorsia AG

2024-05-22 06:12:16 ET More on Idorsia Idorsia Ltd (IDRSF) Q1 2024 Earnings Call Transcript Idorsia Ltd 2024 Q1 - Results - Earnings Call Presentation Idorsia: Aprocitentan Approval Is A Vital News Historical earnings data for Idorsia Financial inform...

2024-05-21 18:20:25 ET Idorsia Ltd (IDRSF) Q1 2024 Results Conference Call May 21, 2024 08:00 AM ET Company Participants Andrew Weiss - SVP, Head of Investor Relations & Corporate Communications Jean-Paul Clozel - Chief Executive Officer André Muller - C...

2024-03-22 11:49:09 ET Summary Idorsia secures $350 million in funding through a collaboration agreement with Viatris, solving immediate liquidity concerns. FDA approves Idorsia's Aprocitentan drug. There is a potential peak sales of over $2 billion. Despite positive developme...

2024-03-20 16:07:27 ET More on Idorsia Historical earnings data for Idorsia Financial information for Idorsia Read the full article on Seeking Alpha For further details see: Idorsia gets FDA approval for hypertension drug Tryvio

Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod. Idorsia to receive an upfront payment of USD 350 million, potential development and regulatory milestone pay...

2023-11-17 05:55:00 ET Summary Biotech sector faces challenges including higher interest rates, inflation, regulatory pressures, and a post-COVID slump. Short interest remains high for some pharmaceutical companies, indicating bearish sentiment. Exchange-traded funds in the bi...

Allschwil, Switzerland – November 3, 2023 Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist for the treatment of patients with resistant hypertension, were presented as an oral presentati...

2023-10-25 05:47:04 ET Idorsia Ltd (IDRSF) First Nine-Month 2023 Earnings Conference Call October 24, 2023 9:00 AM ET Company Participants Andrew Weiss – Senior Vice President, Head of Investor Relations & Corporate Communications Jean-Paul Clozel –...

2023-10-25 04:13:55 ET Summary Including cost saving target, we estimate a 2024 cash burn of CHF 500 million. With current cash and revenue estimates, Idorsia's top priority is to assess potential funding options. QUVIVIQ sales are not picking up as expected, leading to lower reve...

2023-10-24 09:30:11 ET More on Idorsia Idorsia's Insomniac Earnings And The Sell Signal That Won't Sleep Idorsia Ltd 2023 Q2 - Results - Earnings Call Presentation Idorsia Ltd (IDRSF) Q2 2023 Earnings Call Transcript Historical earnings data for Idorsia ...